Bayer To Invest $700M For Hemophilia A Drugs Production In Germany

Bayer announced it will invest more than 500 million euros or nearly $700 million to establish additional capacities for the manufacture of recombinant factor VIII (rFVIII) hemophilia A drugs currently under development.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news